Pathologic Complete Response in Pancreatic Cancer – Doubling Survival Rates

In patients with early-stage pancreatic cancer , achieving a pathologic complete response after preoperative chemotherapy (or radiotherapy) and surgery can double the five-year overall survival rate. These findings came from a multicenter cohort study, which also found that factors such as treatment type and tumor characteristics played an important role in these outcomes.

Resectable Pancreatic Cancer

Over the past decade, treatment of localized (early-stage) pancreatic adenocarcinoma has evolved through the use of preoperative chemotherapy (or radiotherapy), particularly with the increasing use of multiagent chemotherapy regimens.

Preoperative (neoadjuvant) treatment offers a chance of better disease control while allowing selection of patients with more favorable tumor biology for surgical tumor removal. This allows successful surgical removal of the tumor in 77%, 61%, and 22% of patients with resectable, borderline resectable, and locally advanced pancreatic cancer, respectively.

Interpreting anatomical, biological, and other conditional parameters during individualized restaging is difficult. The residual tumor burden after surgical resection following preoperative treatment is an important indicator of the disease's biological response. The presence and extent of viable tumor burden indicate how the tumor has responded to preoperative treatment and can be used to predict disease progression and guide decisions about additional treatment (adjuvant therapy). Pathologic complete response (pCR) means that the tumor has completely disappeared, and its probability is approximately 4%.

Radiotherapy and prolonged preoperative chemotherapy have been associated with pathologic complete response (pCR). Pathologic complete response is linked to improved overall survival (OS), with a median of up to 100 months. However, disease may recur in up to half of patients who achieve a pathologic complete response. Evidence on pathologic complete response is generally based on large national databases with limited detail or small single-center studies.

A better understanding of the outcomes and factors associated with pathologic complete response could contribute to improving preoperative treatment, selecting patients for surgery, and predicting prognosis in pancreatic adenocarcinoma. This international, observational, multicenter cohort study therefore aimed to provide an in-depth analysis of the incidence, outcomes, and associated factors of pathologic complete response in a large group of patients with pancreatic adenocarcinoma who received preoperative chemotherapy (or radiotherapy) followed by surgical resection.

Study Design

The use of preoperative chemotherapy (or radiotherapy) in localized pancreatic adenocarcinoma is increasing, and this treatment approach may improve the chance of pathologic complete response. Achieving a pathologic complete response has been associated with substantial improvements in overall survival. However, the available evidence is generally based on large national databases or small single-center studies, and multicenter studies providing detailed data are lacking.

In this analysis, the researchers examined the incidence of pathologic complete response and associated factors in 1758 patients with localized pancreatic adenocarcinoma who underwent surgical resection after preoperative chemotherapy (or radiotherapy) (mean age, 64 years; 50% male). Patients were treated at 19 centers in eight countries. Median follow-up was 19 months.

Definition of Pathologic Complete Response: Pathologic complete response was defined as the absence of viable tumor cells in the patient's sampled pancreatic tissue after surgical resection.

Factors Examined:

• Overall Survival: Patient survival times were analyzed using a Cox proportional hazards model.
• Pathologic Complete Response: The incidence of pathologic complete response and associated factors were investigated using logistic regression models.

This study provides important information for understanding the rate of pathologic complete response achieved with preoperative treatment in localized pancreatic adenocarcinoma and its effects on overall survival. The analysis may help optimize preoperative treatment approaches and better inform treatment decisions.

Key Findings

• Pathologic Complete Response Rate:

  • The pathologic complete response rate among patients receiving preoperative chemotherapy (or radiotherapy) was 4.8%.

• Reduction in the Risk of Death:

  • Achieving a pathologic complete response was associated with a 54% reduction in the risk of death (hazard ratio, 0.46).

• Five-Year Survival Rate:

  • The five-year overall survival rate was 63% in patients who achieved a pathologic complete response and 30% in those who did not.

• Higher Response with Modified FOLFIRINOX:

  • 58.8% of patients who received preoperative modified FOLFIRINOX achieved a pathologic complete response, compared with 44.7% in the other treatment groups.

• Tumors in the Head of the Pancreas:

  • Tumors in the head of the pancreas were more strongly associated with pathologic complete response (odds ratio [OR], 2.51).

• Large Tumors (> 40 mm):

  • Tumors measuring > 40 mm at diagnosis were associated with pathologic complete response (OR, 2.58).

• Radiologic Response:

  • A partial or complete radiologic response was strongly associated with pathologic complete response (OR, 13.0).

• Serum Carbohydrate Antigen 19-9:

  • Normal or normalized serum carbohydrate antigen 19-9 levels after preoperative treatment were associated with pathologic complete response (OR, 3.76).

• Radiotherapy and Stereotactic Body Radiotherapy:

  • Preoperative radiotherapy (OR, 2.03) and preoperative stereotactic body radiotherapy (OR, 8.91) were associated with pathologic complete response.
  • However, preoperative radiotherapy did not improve overall survival, and preoperative stereotactic body radiotherapy was independently associated with worse overall survival.

• A Response That Is Not Optimal:

  • These findings indicate that pathologic complete response does not always reflect an optimal disease response.

In conclusion, pathologic complete response is associated with better overall survival, although it does not indicate a cure. Factors associated with pathologic complete response may inform treatment decisions.